

10.1071/RD20068_AC

© CSIRO 2020

Supplementary Material: *Reproduction, Fertility and Development*, 2020, 32(13), 1145–1155

Supplementary Material

Generation and characterisation of a COV434 cell clone carrying a monoallelic *FecB^B* mutation introduced by CRISPR/Cas9

Kai Zhang^A, Peiqing Cong^A, Delin Mo^A, Yaosheng Chen^A and Zuyong He^{A,B}

^AState Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, No.3

Road of Higher Education Mega Centre North, Guangzhou 510006, P. R. China.

^BCorresponding author. Email: zuyonghe@foxmail.com




Fig. S1. Schematic diagram of the technical route.




Fig. S2. Evaluation of the cumulus expansion-related genes (*HAS2*, *PTGS2*, and *PTX3*) in the same cell strain under different treatments, BMP15, GDF9, and BMP15+GDF9. NC indicates the cells given no treatment.




Fig. S3. Evaluation of estradiol secretion in the same cell strain under different treatments, BMP15, GDF9, and BMP15+GDF9. NC indicates the cells given no treatment.




Fig. S4. Chromatogram of Sanger sequencing of potential off-target sites. The protospacer adjacent motif (PAM) is labeled in red. The Cas9 cleavage site on each target site is indicated by an arrow head.

Table S1. Sequences of sgRNA oligos

Oligo	Sequence (5' to 3')
sgRNA-top	CACCGTATATCAGACAGTGTTGATG
sgRNA-bottom	AAACCATCAACACTGTCTGATATAAC

Table S2. Sequences of primers used for T7E1 assay

Oligo	Sequence (5' to 3')	Amplicon size (bp)
T7E1-F	TTATCGTCCCTGGTCTG	974
T7E1-R	CTCGCATTCCCTGTTCT	

Table S3. Information of antibodies used in this study

Antibodies used for Western Blot (WB) were diluted in tris buffered saline (TBS) solution containing 3% bovine serum albumin (BSA) (w/v), for Flow Cytometric Analysis(F) were diluted in PBS solution

Antibody	Category	Application	Brands	Cat No.	Dilution Rate(v/v)
BMPR1B	Primary Antibody	F	abcam	ab175385	1:250
P-Smad1/5	Primary Antibody	WB	CST	9516S	1:1000
P-Smad2	Primary Antibody	WB	CST	3108S	1:1000
P-Smad3	Primary Antibody	WB	CST	9520S	1:1000
HSD3B2	Primary Antibody	WB	abcam	ab154385	1:500
GAPDH	Primary Antibody	WB	proteintech	10494-1-AP	1:3000
Beta Tubulin	Primary Antibody	WB	abcam	ab179513	1:2500
Anti-Rabbit IgG (Goat)	Secondary Antibody	WB	Pekin Elmer	NEF812001EA	1:5000
Anti-rabbit IgG (H+L), F(ab')2 Fragment	Secondary Antibody	F	CST	4412	1:750

Table S4. Sequences of primers used for qPCR

Oligo	Sequence (5' to 3')	Amplicon size (bp)	Accession ID of
			target gene
<i>BMPR1B</i> -F	CTTTGCGAAGTGCAGGAAAAT	130	NM_001256792
<i>BMPR1B</i> -R	TGTTGACTGAGTCTTCTGGACAA		
<i>Has2</i> -F	CTCTTTGGACTGTATGGTGCC	205	NM_005328
<i>Has2</i> -R	AGGGTAGGTTAGCCTTTCACCA		
<i>Ptgs2</i> -F	CTGGCGCTCAGCCATACAG	94	NM_000963
<i>Ptgs2</i> -R	CGCACTTATACTGGTCAAATCCC		
<i>Ptx3</i> -F	AGGCTTGAGTCTTTAGTGCC	94	NM_002852
<i>Ptx3</i> -R	ATGGATTCCCTTTGTGCCATAG		
β - <i>actin</i> -F	CATGTACGTTGCTATCCAGGC	250	NM_001101
β - <i>actin</i> -R	CTCCTTAATGTCACGCACGAT		

Table S5. Details of the potential off-target sites

Name	Sequence (5' to 3')	PAM	Score	Chromosome	Strand	Position
OTS-1	GAAATCAGACAGTGTGATG	GAG	5.383333	chr13	-	95506683
OTS-2	TGTTTCAGACTGTGTGATG	GAG	1.650235	chr13	+	74972914
OTS-3	TGTAAGAGACAGTGTGATG	CGG	1.514493	chr16	-	85010610
OTS-4	TTAACATCAGACATTGTGATG	AGG	1.49872	chr12	+	130836020
OTS-5	ATGATCATACAGTGTGATG	TGG	1.457521	chr11	+	99225661

Table S6. Sequences of primers used for off-target analysis

Oligo	Sequence (5' to 3')	Amplicon size (bp)
OTS1-F	ACATGGGATGGACTGGTGGA	787
OTS1-R	GGGTGATGTGGGATTCAAAC	
OTS2-F	AGTGGCCAGAACGTCACAAA	916
OTS2-R	AGCCAATTGGGGCTCAACT	
OTS3-F	GTTGCCTGAAAGGGCATCTG	457
OTS3-R	GTACCAGGCCACAAAGTGACTA	
OTS4-F	CATGCAAACAATTCCCACAG	962
OTS4-R	CGTGAAATGGGGACAGTGGTA	
OTS5-F	GGTTACCGCTGGAAAGGCTA	966
OTS5-R	GGGATCCTAAAGACCCTCACG	

Table S7. Sequence of ssODN oligo

Oligo	Sequence (5' to 3')
ssODN	GAAGCCAGCTGGTTCAGAGAGACAGAAATATCGGACAGTGTG ATGCGCCATGAAAACATTGGGTGAGTAAAGTCTGCATAGCTA

Table S8. Genotype and translational prediction of COV434 single cell derived clones

ID	Genotype	Size of indels	Description	Protein translation	Premature stop codon
1	Biallelic	18bp deletion.	2 nd -19 th nt before PAM	BMPR1B ^{△248-253}	NO
		10bp deletion	1 st -10 th nt before PAM	KO	YES
2	Biallelic	4bp deletion.	5 th -8 th nt before PAM	KO	YES
		3bp substitution	HDR	HDR	NO
3	Biallelic	3bp substitution	HDR	HDR	NO
		1bp deletion	4 th nt before PAM	KO	YES
4	WT	WT	WT	WT	NO
		WT	WT	WT	NO
5	WT	WT	WT	WT	NO
		WT	WT	WT	NO

6	Biallelic	3bp deletion	3 rd -5 th nt before PAM	BMPR1B ^{△253}	NO
		2bp insertion	1 st -2 nd nt before PAM	KO	YES
7	WT	WT	WT	WT	NO
		WT	WT	WT	NO
8	Biallelic	1bp insertion	1 st nt before PAM	KO	YES
		1bp deletion	2 nd nt before PAM	KO	YES
9	Homozygous	1bp deletion	2 nd nt before PAM	KO	YES
		1bp deletion	2 nd nt before PAM	KO	YES
10	Biallelic	5bp deletion	5 th -6 th and 8 th -10 th nt before PAM	KO	YES
		1bp deletion	1 st nt before PAM	KO	YES
11	WT	WT	WT	WT	NO
		WT	WT	WT	NO

12	WT	WT	WT	WT	NO
		WT	WT	WT	NO
13	Biallelic	1bp deletion	4 th nt before PAM	KO	YES
		1bp deletion	2 nd nt before PAM	KO	YES
14	WT	WT	WT	WT	NO
		WT	WT	WT	NO
15	Biallelic	1 bp insertion	3 rd nt before PAM	KO	YES
		2bp insertion	4 th nt before PAM	KO	YES
16	WT	WT	WT	WT	NO
		WT	WT	WT	NO
17	Biallelic	6bp deletion	5 th -10 th nt before PAM	BMPR1B ^{△251-252}	NO
		4bp deletion	6 th -9 th nt before PAM	KO	YES

18	WT	WT	WT	WT	NO
		WT	WT	WT	NO
19	WT	WT	WT	WT	NO
		WT	WT	WT	NO
